Abstract:Cutaneous B cell lymphoma (CBCL) is a lymphoproliferative disorder of neoplastic B cell of the skin with a wide range of clinical manifestations. Commonly, the clinical features of CBCL are plaques, nodules, or ulcerative lesions. Skin is one of the common sites for extra-nodal lymphomas in patients with AIDS and B cell type is less common than T cell type. Only recently, the existence of B cell lymphomas presenting clinically in the skin without evidence of extra-cutaneous involvement has been accepted as pri… Show more
“…Indeed, when we stratified AIDS-NHL in our study into systemic and CNS lymphomas, we observed that the increased AIDS-NHL risk was restricted to systemic lymphomas (OR 2.03, 95% CI 1.17-3.53) and not to CNS lymphomas (OR 0.77, 95% CI 0.29-2.04). However, B-cell AIDS-NHL located in the skin are rare [79][80][81] , and in our study only 3% (5/151) of TSPyV seropositive cases, and 2% (1/48) of TSPyV seronegative cases had skin-associated AIDS-NHL. Using the same multiplex serology assay for polyomaviruses, Teras and colleagues found no significant association between TSPyV seropositivity and NHL in immunocompetent people 82 .…”
Background: HIV infection is associated with increased susceptibility to common pathogens which may trigger chronic antigenic stimulation and hyperactivation of B-cells, events known to precede the development of AIDS-associated non-Hodgkin lymphoma (AIDS-NHL).Methods: To explore whether cumulative exposure to infectious agents contributes to AIDS-NHL risk, we tested sera from 199 AIDS-NHL patients (pre-NHL, average lead-time 3.9 years) and 199 matched HIV-infected controls from the Multicenter AIDS Cohort Study (MACS), for anti-IgG responses to 18 pathogens using multiplex serology. Odds ratios and 95% confidence intervals were estimated using conditional logistic regression models.
“…Indeed, when we stratified AIDS-NHL in our study into systemic and CNS lymphomas, we observed that the increased AIDS-NHL risk was restricted to systemic lymphomas (OR 2.03, 95% CI 1.17-3.53) and not to CNS lymphomas (OR 0.77, 95% CI 0.29-2.04). However, B-cell AIDS-NHL located in the skin are rare [79][80][81] , and in our study only 3% (5/151) of TSPyV seropositive cases, and 2% (1/48) of TSPyV seronegative cases had skin-associated AIDS-NHL. Using the same multiplex serology assay for polyomaviruses, Teras and colleagues found no significant association between TSPyV seropositivity and NHL in immunocompetent people 82 .…”
Background: HIV infection is associated with increased susceptibility to common pathogens which may trigger chronic antigenic stimulation and hyperactivation of B-cells, events known to precede the development of AIDS-associated non-Hodgkin lymphoma (AIDS-NHL).Methods: To explore whether cumulative exposure to infectious agents contributes to AIDS-NHL risk, we tested sera from 199 AIDS-NHL patients (pre-NHL, average lead-time 3.9 years) and 199 matched HIV-infected controls from the Multicenter AIDS Cohort Study (MACS), for anti-IgG responses to 18 pathogens using multiplex serology. Odds ratios and 95% confidence intervals were estimated using conditional logistic regression models.
“…In all, 276 published cases of PBL were identified from this search, which was then refined to identify those patients who presented with skin involvement. Twenty such patients were identified and are listed in Table together with their clinico‐pathological features.…”
Plasmablastic lymphoma (PBL) is a recently described rare variant of diffuse large B-cell lymphoma characterised by its aggressive nature and plasmacytic differentiation. It most frequently arises in the oral cavity of human immunodeficiency virus (HIV)-infected patients. However extra-oral involvement is becoming increasingly recognised, particularly in HIV-negative patients. We report a case of PBL presenting as multiple violaceous nodules and plaques on the leg of a HIV-negative patient, 13-years post-renal transplant. To date, 20 cases of PBL presenting in the skin have been reported. We review and compare the clinico-pathological features of these cases.
“…The estimated related risk of NHL associated with HIV infection is 100 times greater than in general population, and the risk increases with the progressive immunosuppression related with retrovirus. 4 More than 90%of HIV-associated NHL is derived from B cells and the majority is high grade. Extranodal presentation is most frequent in HIV-seropositive patients than in general population.…”
Section: Discussionmentioning
confidence: 99%
“…3 Patients with Non Hodgkins Lymphoma showed cutaneous involvement in 15% to 20% of cases and in 5% to 10% of them, skin lesions are the first manifestation of the disease. 4 Here we report a rare case of pyoderma gangrenosum (PG) with coexisting cutaneous non Hodgkins Lymphoma of diffuse large B cell lymphoma type in a HIV positive patient.…”
HIV infection can lead to varied spectrum of associated disease conditions. Pyoderma gangrenosum is a neutrophilic dermatosis that may be associated with myeloid malignancies. Less information is available about the association of pyoderma gangrenosum with lymphoid malignancies. We report a rare case of pyoderma gangrenosum in association with Non hodgkins lymphoma(NHL) of diffuse large B cell type. In this case the lesion which showed NHL features occurred in the perianal region, coexisting with pyoderma gangrenosum lesions in the perianal, lower limb and abdominal region. Another interesting feature is the occurrence of both these conditions in a HIV-positive patient with severe immunologic failure to first line antiretroviral therapy contributing to the refractoriness to treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.